Doxorubicin-Loaded Nanobubbles Combined with Extracorporeal Shock Waves: Basis for a New Drug Delivery Tool in Anaplastic Thyroid Cancer.
暂无分享,去创建一个
R. Cavalli | F. Marano | M. Argenziano | R. Frairia | A. Adamini | O. Bosco | Letizia Rinella | N. Fortunati | M. Catalano
[1] M. Shah,et al. Anaplastic thyroid cancer , 2015, Current opinion in endocrinology, diabetes, and obesity.
[2] Xiaojuan Pang,et al. A dual pH/thermal responsive nanocarrier for combined chemo-thermotherapy based on a copper-doxorubicin complex and gold nanorods. , 2015, Nanoscale.
[3] Chen Jiang,et al. Choline Derivate-Modified Doxorubicin Loaded Micelle for Glioma Therapy. , 2015, ACS applied materials & interfaces.
[4] J. Shah,et al. Anaplastic Thyroid Carcinoma, Version 2.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] M. Ramezani,et al. The chemotherapeutic potential of doxorubicin-loaded PEG-b-PLGA nanopolymersomes in mouse breast cancer model. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[6] P. Giustetto,et al. Preparation and in vitro characterization of chitosan nanobubbles as theranostic agents. , 2015, Colloids and surfaces. B, Biointerfaces.
[7] F. Atyabi,et al. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[8] S. Mane,et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. , 2015, Human molecular genetics.
[9] E. Arvat,et al. Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. , 2014, Thyroid : official journal of the American Thyroid Association.
[10] Chih-Kuang Chen,et al. Polylactide-graft-doxorubicin nanoparticles with precisely controlled drug loading for pH-triggered drug delivery. , 2014, Biomacromolecules.
[11] T. Chou,et al. Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment , 2013, PloS one.
[12] V. D. Di Crescenzo,et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.
[13] A. K. Kondapi,et al. A Target-Specific Oral Formulation of Doxorubicin-Protein Nanoparticles: Efficacy and Safety in Hepatocellular Cancer , 2013, Journal of Cancer.
[14] F. Marano,et al. Histone deacetylase inhibition affects sodium iodide symporter expression and induces 131I cytotoxicity in anaplastic thyroid cancer cells. , 2013, Thyroid : official journal of the American Thyroid Association.
[15] Jingmou Yu,et al. Folic acid conjugated glycol chitosan micelles for targeted delivery of doxorubicin: preparation and preliminary evaluation in vitro , 2013, Journal of biomaterials science. Polymer edition.
[16] Crispin R Dass,et al. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.
[17] Y. Nikiforov,et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.
[18] C. Nucera,et al. FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. , 2012, Endocrine-related cancer.
[19] M. Trotta,et al. New chitosan nanobubbles for ultrasound-mediated gene delivery: preparation and in vitro characterization , 2012, International journal of nanomedicine.
[20] B. Bussolati,et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. , 2012, The Journal of clinical endocrinology and metabolism.
[21] N. Fortunati,et al. Epigenetics Modifications and Therapeutic Prospects in Human Thyroid Cancer , 2012, Front. Endocrin..
[22] B. Bussolati,et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo , 2012, International journal of cancer.
[23] T. Kodama,et al. Evaluation of antitumor effects following tumor necrosis factor‐α gene delivery using nanobubbles and ultrasound , 2011, Cancer science.
[24] S. Remick,et al. Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment , 2011, Journal of oncology.
[25] R. Weber,et al. Anaplastic thyroid carcinoma: palliation or treatment? , 2011, Current opinion in otolaryngology & head and neck surgery.
[26] C. Nucera,et al. Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer. , 2010, Surgery.
[27] J. Copland,et al. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).
[28] Hiroshi Maeda,et al. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.
[29] N. Fortunati,et al. Emerging molecular therapies of advanced thyroid cancer. , 2010, Molecular aspects of medicine.
[30] Richard Manasseh,et al. Cavitation microstreaming and stress fields created by microbubbles. , 2010, Ultrasonics.
[31] Xiang Li,et al. Preparation of nanobubbles for ultrasound imaging and intracelluar drug delivery. , 2010, International journal of pharmaceutics.
[32] Ick Chan Kwon,et al. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[33] Cristina Carvalho,et al. Doxorubicin: the good, the bad and the ugly effect. , 2009, Current medicinal chemistry.
[34] M. Ladanyi,et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.
[35] Raffi Karshafian,et al. Sonoporation by ultrasound-activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability. , 2009, Ultrasound in medicine & biology.
[36] Douglas A Christensen,et al. Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. , 2008, Ultrasonics.
[37] E. Lam,et al. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression , 2008, Molecular Cancer Therapeutics.
[38] I. Kwon,et al. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[39] R. Chiarle,et al. High Energy Shock Waves (HESW) Increase Paclitaxel Efficacy in a Syngeneic Model of Breast Cancer , 2008, Technology in cancer research & treatment.
[40] H. Katus,et al. Impact of microbubbles on shock wave-mediated DNA uptake in cells in vitro. , 2007, Ultrasound in medicine & biology.
[41] G. Ciccone,et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. , 2007, European journal of endocrinology.
[42] R. Frairia,et al. High energy shock waves activate 5'-aminolevulinic Acid and increase permeability to Paclitaxel: antitumor effects of a new combined treatment on anaplastic thyroid cancer cells. , 2007, Thyroid : official journal of the American Thyroid Association.
[43] Kyung-Ja Cho,et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. , 2007, Biomaterials.
[44] O. Bosco,et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. , 2006, The Journal of endocrinology.
[45] A. Gartel,et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. , 2006, Cancer research.
[46] D. L. Le Couteur,et al. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[47] M. Schlumberger,et al. Anaplastic Thyroid Carcinoma , 2003 .
[48] R. Frairia,et al. High Energy Shock Waves (HESW) Enhance Paclitaxel Cytotoxicity in MCF-7 Cells , 2003, Breast Cancer Research and Treatment.
[49] I. Kwon,et al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[50] S. Chow,et al. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer , 2003, Anti-cancer drugs.
[51] Michael R Hamblin,et al. Shock wave-mediated molecular delivery into cells. , 2002, Biochimica et biophysica acta.
[52] J. Ogden,et al. Shock Wave Therapy (Orthotripsy®) in Musculoskeletal Disorders , 2001, Clinical orthopaedics and related research.
[53] M. Israel,et al. Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[54] H. Gharib,et al. Anaplastic thyroid carcinoma: current diagnosis and treatment. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] K Hynynen,et al. Ultrasound technology for hyperthermia. , 1999, Ultrasound in medicine & biology.
[56] P. Hofschneider,et al. Shock wave permeabilization as a new gene transfer method , 1997, Gene Therapy.
[57] J. Lingeman,et al. Extracorporeal Shock Wave Lithotripsy , 1997 .
[58] T. Skovsgaard,et al. Cellular resistance to anthracyclines. , 1996, General pharmacology.
[59] L. Liu,et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.
[60] Ick Chan Kwon,et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. , 2006, Biomaterials.
[61] R. Frairia,et al. High energy shock waves enhance the cytotoxic effect of doxorubicin and methotrexate to human osteosarcoma cell lines. , 2006, Oncology reports.
[62] Y. Nikiforov. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas , 2004, Endocrine pathology.